Show simple item record

dc.contributor.authorIllidge, Timothy M
dc.contributor.authorBayne, Mike
dc.contributor.authorBrown, Nicholas S
dc.contributor.authorChilton, Samantha
dc.contributor.authorCragg, Mark S
dc.contributor.authorGlennie, Martin J
dc.contributor.authorDu, Yong
dc.contributor.authorLewington, Valerie
dc.contributor.authorSmart, James
dc.contributor.authorThom, James
dc.contributor.authorZivanovic, Maureen
dc.contributor.authorJohnson, Peter W
dc.date.accessioned2010-03-15T16:39:37Z
dc.date.available2010-03-15T16:39:37Z
dc.date.issued2009-02-12
dc.identifier.citationPhase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. 2009, 113 (7):1412-21 Blooden
dc.identifier.issn1528-0020
dc.identifier.pmid19074729
dc.identifier.doi10.1182/blood-2008-08-175653
dc.identifier.urihttp://hdl.handle.net/10541/94249
dc.description.abstractThe effect of induction therapy with multiple doses of rituximab on the subsequent efficacy and toxicity of anti-CD20 radioimmunotherapy is unknown. We evaluated a novel protocol using 4 weekly infusions of 375 mg/m(2) rituximab followed by 2 fractions of (131)I-rituximab, preceded by a 100-mg/m(2) predose of rituximab, in relapsed indolent B-cell lymphoma. Induction therapy with rituximab significantly increased the effective half-life of (131)I-rituximab (P = .003) and high serum levels of rituximab after induction therapy correlated with increased effective half-life of the radioimmunoconjugate (P = .009). Patients with large tumor burdens experienced significant increases in the effective half-life of (131)I-rituximab between delivery of the first and second fractions (P = .007). Induction therapy with multiple doses of rituximab did not appear to compromise the clinical efficacy or increase toxicity of subsequent (131)I-rituximab radioimmunotherapy. The overall response rate was 94%, with complete response rate 50%. The median time to progression was 20 months, significantly longer than for the last qualifying chemotherapy (P = .001). Fractionation of (131)I-rituximab allowed cumulative whole-body doses of more than 120 cGy, approximately 60% greater than those previously achieved with a single administration of a murine radioimmunconjugate, to be delivered without significant hematologic toxicity.
dc.language.isoenen
dc.subjectHaemoglobinen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntibodies, Monoclonal
dc.subject.meshDisease-Free Survival
dc.subject.meshDose-Response Relationship, Radiation
dc.subject.meshFemale
dc.subject.meshHemoglobins
dc.subject.meshHumans
dc.subject.meshIodine Radioisotopes
dc.subject.meshLymph Nodes
dc.subject.meshLymphoma, B-Cell
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeutrophils
dc.subject.meshPlatelet Count
dc.subject.meshRadioimmunotherapy
dc.subject.meshSpleen
dc.titlePhase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy.en
dc.typeArticleen
dc.contributor.departmentSchool of Cancer and Imaging Sciences, University of Manchester, Manchester, UK. tmi@manchester.ac.uken
dc.identifier.journalBlooden
html.description.abstractThe effect of induction therapy with multiple doses of rituximab on the subsequent efficacy and toxicity of anti-CD20 radioimmunotherapy is unknown. We evaluated a novel protocol using 4 weekly infusions of 375 mg/m(2) rituximab followed by 2 fractions of (131)I-rituximab, preceded by a 100-mg/m(2) predose of rituximab, in relapsed indolent B-cell lymphoma. Induction therapy with rituximab significantly increased the effective half-life of (131)I-rituximab (P = .003) and high serum levels of rituximab after induction therapy correlated with increased effective half-life of the radioimmunoconjugate (P = .009). Patients with large tumor burdens experienced significant increases in the effective half-life of (131)I-rituximab between delivery of the first and second fractions (P = .007). Induction therapy with multiple doses of rituximab did not appear to compromise the clinical efficacy or increase toxicity of subsequent (131)I-rituximab radioimmunotherapy. The overall response rate was 94%, with complete response rate 50%. The median time to progression was 20 months, significantly longer than for the last qualifying chemotherapy (P = .001). Fractionation of (131)I-rituximab allowed cumulative whole-body doses of more than 120 cGy, approximately 60% greater than those previously achieved with a single administration of a murine radioimmunconjugate, to be delivered without significant hematologic toxicity.


This item appears in the following Collection(s)

Show simple item record